Interact with experts and peers.

Recent Posts

10 of 33 Shown
  • How Does the AASLD/IDSA HCV Guidance Weigh in on Management of HIV Coinfection?

    Douglas T. Dieterich MD - 10/9/2014
    There is great interest in offering coinfected patients the same opportunity for cure as monoinfected patients. The AASLD/IDSA guidance has developed recommendations aimed at maximizing cure in different populations of coinfected individuals.
  • My Take on the Guidance From AASLD/IDSA for Treating Interferon-Ineligible Patients With Genotype 1 HCV Infection

    Paul Y. Kwo MD - 10/9/2014 1 comment / Last Comment: 10/16/2014
    Historically, evaluating patients for interferon eligibility was critical. Today, interferon-free regimens are evolving and soon they will be standard practice for even the most difficult-to-treat disease.
  • Delivering on the Promise: Maximizing SVR in the Real World

    Jordan J. Feld MD, MPH - 10/6/2014 3 comments / Last Comment: 10/13/2014
    Delivering the successes of recent HCV therapy trials to the real world will take some work, but here is how it can be achieved.
  • Prioritizing Patients for HCV Therapy: The Case for Treating Before Advanced Disease

    Nancy Reau MD - 9/23/2014 3 comments / Last Comment: 10/4/2014
    Despite remarkable advances in curative treatments for HCV, many patients are being denied insurance coverage, as priority access to these costly medications is given to those with advanced disease.
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014 4 comments / Last Comment: 9/18/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
  • Genotype 1 HCV–Infected Cirrhotic Patients: Still Hard to Treat?

    Mark S. Sulkowski MD - 6/27/2014 6 comments / Last Comment: 9/24/2014
    After a long wait, the great majority of cirrhotic patients now has a realistic chance of achieving HCV cure.
  • My Approach to Identifying Treatment Candidates and Maintaining Patients on Long-term HBV Therapy

    Anna S. F. Lok MD - 6/19/2014 8 comments / Last Comment: 8/13/2014
    I find it helpful to discuss the impact of treatment on liver fibrosis/cirrhosis and hepatocellular carcinoma with patients, which motivates some to initiate and adhere to their long-term treatment.
  • Post-EASL Update: What Is the Role of Treatment Guidelines in the Current HCV Era?

    Jordan J. Feld MD, MPH - 5/22/2014 8 comments / Last Comment: 8/26/2014
    With the new era of HCV therapies comes a new era in clinical guidelines; although there is certainly overlap, the major guidelines serve different but important roles.
  • Post-EASL Update: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed

    Stefan Zeuzem MD - 5/19/2014 7 comments / Last Comment: 8/31/2014
    Following new data from the ION-2 study reported at EASL 2014, options for retreatment of patients with previous PI failure appear much improved.
  • Treating HBV Patients With Cirrhosis: The Need for Vigilant HCC Screening

    Maria Buti MD - 5/14/2014 6 comments / Last Comment: 10/3/2014
    Antiviral therapy can dramatically improve liver histology, even in cirrhotic patients, but it remains critical to screen patients with suppressed viral load for hepatocellular carcinoma.
10 of 33 Shown
Show 10 More